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Animal models that mimic human diabetic nephropathy
are useful to identify key factors in pathogenesis of this
disease, as well as the development of new therapies. Several
mouse models of diabetes have features of human diabetic
nephropathy, yet none of these completely fulfill the Animal
Models of Diabetes Complications Consortium criteria and
completely reproduce pathological and functional features of
the human disease. The Akita mouse carries a mutation in the
insulin-2 gene and, to date, only survives as heterozygotes
that develop spontaneous type 1 diabetes. Here we show
that Akita mice with mutation of both insulin-2 alleles
(Akita knockout (KO)) survive if crossed onto the Balb/c
background. These mice develop hyperglycemia, more
severe albuminuria, and mesangial sclerosis compared with
heterozygous mice on the same genetic background.
Interestingly, crossing these AkitaKO mice with integrin a1KO
mice, a model of exacerbated glomerulosclerosis after injury
and also on the Balb/c background, resulted in a 16-fold
increase in albuminuria, significant mesangial matrix
expansion, nodular and diffuse glomerulosclerosis, and
a 2-fold increase in glomerular basement membrane
thickening when compared with nondiabetic mice. Moreover,
a significant decline in glomerular filtration was evident in
the a1KOAkitaKO mice at 6 months of age. Thus, the integrin
a1KOAkitaKO Balb/c mouse represents a promising model
presenting with most features of human diabetic
nephropathy.
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Diabetic nephropathy (DN) is now the leading cause of end-
stage renal disease in the developed world, and its incidence
has increased by more than 50% in the past 10 years. It is
initially characterized by glomerular hyperfiltration, glomer-
ular and tubular epithelial hypertrophy, and microalbumin-
uria. In established DN, there is decreased renal function,
which is accompanied by glomerular basement membrane
(GBM) thickening, glomerular sclerosis, and interstitial
fibrosis.1,2
Animal models of DN that closely recapitulate the features
of human disease would be useful tools in understanding
the pathogenesis and developing new treatment strategies for
this devastating disorder. A good model should have the
characteristics required by the Animal Models of Diabetes
Complications Consortium (AMDCC, http://www.DiaComp.
org), which includes greater than a 50% decline in
glomerular filtration rate (GFR) over the lifetime of the
animal; greater than 10-fold increase in albuminuria; greater
than a 50% increase in GBM thickness; and typical renal
pathologic changes (mesangial matrix expansion, nodular
glomerulosclerosis, mesangiolysis, arteriolar hyalinosis, tubulo-
interstitial fibrosis).3,4
As a platform for developing models of diabetic
complications, several mouse lines show promise. db/db
mice, which carry a mutation of the leptin receptor gene,
have been widely used as models of type 2 diabetes,5 although
they only develop mild nephropathy.5,6 Improvement to this
model was made by crossing the db/db with mice lacking the
endothelial cell nitric oxide synthase (eNOS).7 db/db-
eNOS/ mice have hyperglycemia evident by approxi-
mately 6–8 weeks of age and exhibit an accelerated model of
type 2 DN with increased systolic blood pressure, albumin-
uria, mesangial expansion, nodular glomerulosclerosis,
thickening of the GBM, and decrease in GFR.7 More recently,
it was shown that BTBR ob/ob mice, which carry a mutation
of the leptin gene, develop progressive proteinuria, glomer-
ular lesions similar to those of advanced human DN
with thickening of the GBM, focal arteriolar hyalinosis,
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mesangiolysis, and focal mild interstitial fibrosis.8 Among the
mouse model of type 1 diabetes, the C57Bl/6 eNOS/
mouse is the best option for studying features of advanced
DN. Upon injection with streptozotocin, the C57Bl/6
eNOS/ mice develop nephropathy and produce lesions
that closely mimic human glomerulopathy and tubulointer-
stitial disease.9 However, streptozotocin-mediated DN
comes with pitfalls including drug toxicity and drug
instability. Thus, animal models that develop spontaneous
diabetes are preferable. The Akita mouse is one of the first
described mouse models for spontaneous type 1 diabetes.
These mice have a single-nucleotide substitution in the
insulin-2 gene (C96Y), originally identified as a spontaneous
mutation in a colony of C57BL/6 mice.10 Heterozygosity for
the mutation in male C57BL/6 mice (þ /C96Y, here referred
to as Akita-het) is associated with marked hyperglycemia,
whereas homozygosity (C96Y/C96Y, here referred to as
Akita knockout (AkitaKO)) leads to perinatal lethality.
However, the renal injury in heterozygous mice is only
moderate, which is consistent with the well-accepted finding
that C57BL/6 mice are more resistant to renal injures
than other backgrounds.11,12 Efforts have been made to
improve this model by crossing the Akita mice into
different genetic backgrounds,11,12 deleting the angiotensin-
converting enzyme-2 (ref. 13) or the bradykinin receptors.14
Yet, although progress has been made, none of these
crosses have yielded a robust mouse model that
reproduces the pathological and functional features of
human DN.3
In an attempt to make the Akita a better model of DN, we
crossed these mice onto the Balb/c background. Unlike other
backgrounds, Akita mice with both insulin-2 alleles mutated
(AkitaKO) survive on the Balb/c background. These mice
developed more severe DN than heterozygous litters
(Akita-het), which included mesangial expansion, glomer-
ulosclerosis, and GBM thickening. However, no nodular
glomerulosclerosis or significant GFR decline was observed
in the AkitaKO mice. For this reason, we hypothesized that
crossing the Balb/c AkitaKO with a mouse model of
exacerbated glomerular injury might result in more severe
DN. One such model is the integrin a1–null (a1KO)
mouse, which we have previously shown to develop more
severe glomerular injury following adriamycin-induced
nephropathy15 or streptozotocin-induced diabetes,16 espe-
cially on a Balb/c background. We therefore crossed
the AkitaKO with integrin a1KO mice to determine whether
the a1KOAkitaKO mouse developed more severe DN. We
show that BALB/c a1KOAkitaKO mice show a 16-fold
increase in albuminuria, severe glomerulosclerosis with
nodules, a significant decline of GFR over their lifetime,
and 2-fold thickening of the GBM when compared
with nondiabetic Balb/c mice. Thus, the Balb/c integrin
a1KOAkitaKO mice develop a series of renal abnormalities
that closely resemble advanced human DN, making
this strain particularly attractive for testing therapeutic
interventions.
RESULTS
BALB/c Akita mice with both insulin-2 alleles mutated
(AkitaKO) are viable and develop DN
In an attempt to generate better mouse models of DN, Akita
mice (originally on the C57BL/6 background) were back-
crossed onto the Balb/c background. Balb/c Akita with both
insulin-2 alleles mutated (AkitaKO) can be generated
(Supplementary Figure S1A and S1B online), and they
survive up to 6 months of age, which contrasts with C57BL/6
mice, which only survive as heterozygotes. When the
AkitaKO mice were followed up over time, they showed
significant reduction in body weight at 4 and 6 months of
age, whereas Akita-het mice maintained a body weight
similar to that of nondiabetic mice (Figure 1a). Although the
AkitaKO mice can survive up to 6 months of age,B20% had
to be killed before this time because of failure to thrive.
To determine whether there were differences in renal
function between the Akita-het and AkitaKO mice, we
measured GFR at the age of 4 and 6 months (Figure 1b).
Early stages of DN are often characterized by hyperfiltration,
whereas a decline in GFR is a marker of disease progression
to end-stage kidney failure.17 The GFR was significantly
elevated in Akita-het mice at 6 months; however, in the
AkitaKO, increased GFR was already evident at 4 months,
and it was decreased by 6 months. When albuminuria was
assessed by measuring albumin-to-creatinine ratio, there was
approximately a 3-fold increase in albumin-to-creatinine
ratio in both 4-month old Akita-het and AkitaKO mice
compared with nondiabetic mice (Figure 1c). Increased
albuminuria only persisted in the AkitaKO mice at 6 months
of age (Figure 1c).
When the kidneys were subjected to pathological exam-
ination, mesangial matrix expansion was present in both
Akita-het and AkitaKO mice at the 4-month time point,
although it was more pronounced in the latter group as
assessed by a glomerulosclerosis score (Figure 2a and b). The
same degree of glomerular injury was present in both
genotypes at 6 months of age, and there was no evidence of
tubular injury (Figure 2c and d).
Taken together, these data verify that Akita homozygote
mice can be generated on a Balb/c background and they
develop more accelerated DN than heterozygote mice on the
same background. Despite this increased rate of disease
development, the Akita homozygote mice only develop mild
glomerular injury primarily characterized by mesangial
expansion.
AkitaKO mice crossed with the integrin a1KO mice develop
robust DN
To develop a more robust mouse model of DN than that seen
in the AkitaKO mice on the Balb/c background, we crossed
the AkitaKO mice with integrin a1–null (a1KO) mice on the
same background. The rationale behind this cross is 3-fold:
(1) integrin a1b1 is a negative regulator of collagen
homeostasis, and loss of this receptor leads to increased
collagen synthesis;18 (2) mice lacking integrin a1b1 develop
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excessive fibrosis following injury;15,16 and (3) integrin a1KO
Balb/c mice develop more exacerbated glomerular injury
compared with wild-type mice following induction of type 1
diabetes.16 Integrin a1KOAkitaKO mice were successfully
generated (Supplementary Figure S1A and S1B online), and
these mice developed similar levels of hyperglycemia when
compared with AkitaKO throughout the duration of the
study (Supplementary Figure S1C online). Both AkitaKO and
a1KOAkitaKO showed a significant drop in weight relative to
nondiabetic wild-type or integrin a1KO mice at both 4 and
6 months of age (Figure 3a). Approximately 40% of the
a1KOAkitaKO mice had to be killed before completion of the
study because of failure to thrive.
When GFR was measured in the mice at 4 and 6 months,
there was an equal rise in GFR in the AkitaKO and
a1KOAkitaKO mice at 4 months. At 6 months of age, GFR
declined in both AkitaKO and a1KOAkitaKO mice; however,
this drop was only significant in the latter group with an
overall B50% decline compared with 4-month-old diabetic
mice (Figure 3b). No changes in GFR were observed between
nondiabetic wild-type and integrin a1KO mice throughout
the study (Figure 3b). Measurement of albumin-to-creatinine
W
T
4 Months 6 Months
Ak
ita
KO
W
T
WT
*
*
*
*
#
Ak
ita
KO
AkitaKO
WT
AkitaKO
3
G
lo
m
er
ul
os
cle
ro
sis
sc
o
re
G
lo
m
er
ul
os
cle
ro
sis
sc
o
re
2
1
0
3
2
1
0
Ak
ita
-h
et
Ak
ita
-h
et
Akita-het Akita-het
Figure 2 |Histopathology of kidneys from AkitaKO Balb/c
mice. (a, c) Representative light micrographs of periodic acid
Schiff–stained kidney sections from wild-type (WT), Akita-het, and
AkitaKO mice at 4 (a) and 6 (c) months of age. (b, d) Mesangial
sclerosis index was evaluated in kidneys from 4- (b) and
6- (d) month-old nondiabetic and diabetic mice in a blinded
manner, and the percent of mesangial matrix occupying the
glomerulus was scored as 1, 0–24%; 2, 25–49%; 3, 50–74%; and 4,
475%. Data are presented as the mean±s.d. of 120 glomeruli
(30 glomeruli/mouse with a total of four mice evaluated). Both
Akita-het and AkitaKO mice developed mild-to-moderate
mesangial matrix expansion at 4 and 6 months of age compared
with the control WT mice. * and # are as in Figure 1. KO, knockout.
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Figure 1 |Physiological parameters of AkitaKO Balb/c mice.
Body weight (a), glomerular filtration rate (GFR; b), and urine
albumin excretion (c) in 4- and 6-month-old wild-type (WT),
Akita-het, and AkitaKO mice BALB/c mice. Values represent the
mean±s.d. of the mice indicated. Differences between
nondiabetic and Akita-het or AkitaKO mice (*), or Akita-het and
AkitaKO within the same age group (#), were significant with
Po0.05. ACR, albumin-to-creatinine ratio; KO, knockout.
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ratio in 4- and 6-month-old mice revealed an B3-fold
increase in albumin excretion in AkitaKO mice vs. B16-fold
increase in the a1KOAkitaKO mice compared with nondia-
betic mice (Figure 3c).
Increased glomerular injury in diabetic integrin a1KOAkitaKO
mice
We next defined the histopathological features of the kidneys
of the a1KOAkitaKO mice at 4 and 6 months in order to
define the severity of disease in these mice. There was
significantly increased mesangial matrix expansion (Figure 4a
and c) and glomerulosclerosis score (Figure 4b and d) in the
a1KOAkitaKO when compared with the AkitaKO mice at
both 4 and 6 months. Because of the severity of the
glomerular injury in these mice, we carefully defined the
histological lesions found within the glomeruli of the
a1KOAkitaKO mice. As shown in Figure 5, there was
evidence of diffuse and nodular mesangial sclerosis, as well
as mesangiolysis seen under light microscopy. The mesangial
expansion was confirmed on electron microscopy in both the
AkitaKO and a1KOAkitaKO mice at 6 months; however, it
was much more severe in the latter group (Figure 6a).
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Figure 3 |Physiological parameters of integrin a1KOAkitaKO
Balb/c mice. Body weight (BW; a), glomerular filtration rate
(GFR; b), and urine albumin excretion (c) in 4- and 6-month-old
wild-type (WT), AkitaKO and integrin a1KOAkitaKO BALB/c
mice. Values represent the mean±s.d. of the mice indicated.
Differences between nondiabetic and AkitaKO or a1KOAkitaKO
mice (*), or AkitaKO and a1KOAkitaKO within the same age group
(#), or 4-month vs. 6-month-old a1KOAkitaKO mice (**) were
significant with Po0.05. KO, knockout.
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Figure 4 |Histopathology of kidneys from a1KOAkitaKO
Balb/c mice. (a, c) Representative light micrographs of periodic
acid Schiff–stained kidney sections from wild-type (WT), integrin
a1KO, AkitaKO, and a1KOAkitaKO mice at 4 (a) and 6 (c) months
of age. Both AkitaKO and a1KOAkitaKO mice developed
mesangial matrix expansion at 4 months of age, although it was
more severe in the latter group (a). The increased mesangial
expansion was worse in the a1KOAkitaKO mice at 6 months of
age, and there was evidence of nodular glomerulosclerosis
(arrow), which was not present in the AkitaKO mice (c).
(b, d) Mesangial sclerosis index was evaluated in kidneys from the
mice indicated above and the percentage of mesangial matrix
occupying the glomerulus scored as described in Figure 1. Data
are presented as the mean±s.d. of 120 glomeruli (30 glomeruli/
mouse with a total of four mice evaluated). Although both
AkitaKO and a1KOAkitaKO mice developed glomerular injury at 4
and 6 months of age, the degree of injury was significantly higher
in the latter group. *, **, and # are as in Figure 3. KO, knockout.
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Furthermore, there was GBM thickening in both genotypes
compared with nondiabetic controls, which was significantly
more severe in the a1KOAkitaKO mice (Figure 6a and b).
Collagen IV is the most abundant extracellular matrix
component in the glomerulus, and its upregulation has been
described in many glomerular diseases, including DN.16
Analysis of 6-month-old mice revealed increased glomerular
collagen IV deposition in both AkitaKO and a1KOAkitaKO
mice compared with nondiabetic mice, although it was more
abundant in the latter group (Figure 7a and b). Furthermore,
excessive fibrillar collagen deposition in the a1KOAkitaKO
mice was confirmed by trichrome staining in both diffuse and
nodular mesangial lesions (Figure 7c).
One of the features of the glomerular lesions of DN is
collapse of the glomerular tufts due to scar tissue consisting
of extracellular matrix.19 To define the area occupied by the
α1KOAkitakO
Nodular sclerosis
A B C D
Mesangial expansion Diffuse sclerosis Mesangiolysis
Figure 5 |Characterization of the glomerular injury in the a1KOAkitaKO Balb/c mice. Representative light micrographs of glomeruli
stained with Jones’ (a, b), periodic acid–Schiff (c), and Masson’s trichrome (d) stains from 6-month-old a1KOAkitaKO mice. Note the presence
of nodular glomerulosclerosis (A), mesangial expansion (B), diffuse glomerulosclerosis (C), and mesangiolysis (D). KO, knockout.
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glomerular capillaries, we stained kidney-frozen sections of
6-month old nondiabetic and diabetic mice with CD31, a
well-defined marker of blood vessels. Compared with
nondiabetic mice, there were significantly decreased CD31-
positive structures in the glomeruli of both AkitaKO and
a1KOAkitaKO mice, and this reduction was much more
evident in the latter group (Figure 8).
Taken together, these results show that a1KOAkitaKO
mice develop more severe DN than AkitaKO mice, which is
characterized by the development of excessive albuminuria,
severe glomerulosclerosis, which is both diffuse and nodular,
mesangiolysis, marked thickening of the GBM, excessive
collagen deposition, significant decline in GFR, and
decreased glomerular capillary loops over the lifetime of
the mouse.
No significant tubulointerstitial fibrosis is evident in diabetic
integrin a1KOAkitaKO mice
One of the hallmarks of late stages of DN is the development
of tubulointerstitial fibrosis. On examination by light
microscopy of the kidneys, no evidence of severe tubuloin-
terstitial fibrosis was seen (Figures 2 and 4). However, we
wanted to define subtle changes that might be present in the
tubulointerstitium of the AkitaKO and a1KOAkitaKO mice.
We therefore examined the tubulointerstitium by electron
microscopy to define tubular morphology and tubular
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of glomeruli of 6-month-old WT, AkitaKO, and a1KOAkitaKO mice. The upper panels demonstrate increased mesangial expansion (asterisk)
in the AkitaKO mice, which is significantly worse in the a1KOAkitaKO mice. Bar¼ 2 mm. Obvious increase in the thickness of the GBM
was evident in both AkitaKO and a1KOAkitaKO mice at 6 months (lower panel in a; bar¼ 2 mm), although it was more prominent in the
latter group (b). Values in b represent the mean±s.d. of 30 measurements. Differences between (*) or AkitaKO vs. a1KOAkitaKO mice (#)
were significant (Po0.05). GBM, glomerular basement membrane; KO, knockout; WT, wild type.
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basement membrane thickness in the kidneys of 6-month-old
wild-type, AkitaKO, and a1KOAkitaKO mice (Figure 9a). No
differences in any of the parameters analyzed were seen
between the three genotypes. We next co-stained kidney
paraffin sections for collagen I and Dolichos biflorus
agglutinin (a glycoprotein that binds the apical aspect of
CD cells,20) to define whether there was increased collagen I
in the tubulointerstitial compartment (Figure 9b). A small,
but equal increase in collagen I staining was seen in both
AkitaKO and a1KOAkitaKO mice when compared with
nondiabetic wild-type animals. When we immunostained
with anti-a-smooth muscle actin antibodies to define
whether there were increased interstitial fibroblasts or
whether tubular cells had acquired a more mesenchymal
morphology, no differences were seen between the genotypes
(Figure 9b). Finally, no differences in tubular integrity were
seen in the different genotypes when kidneys were immu-
nostained with anti-E-cadherin antibodies (Figure 9c). Thus,
other than a minimal increase in collagen I expression, there
was negligible tubulointerstitial disease in the AkitaKO and
a1KOAkitaKO mice at 6 months of age.
DISCUSSION
The overall goal of this study was to use the Akita mouse as a
platform to generate a mouse model that would fulfill many
of the AMDCC criteria and reproduce most, if not all, of the
pathological and functional features of human DN. Whereas
most Akita mouse strains generated so far only survive as
heterozygotes, we show that AkitaKO mice can be generated
when crossed onto the BALB/c background. These mice
develop more severe albuminuria and mesangial sclerosis
than heterozygous mice. We also show that crossing the
AkitaKO mice with integrin a1KO mice results in a 16-fold
increase in albuminuria, diffuse and nodular mesangial
sclerosis, mesangiolysis, and a 2-fold increase in GBM
thickening compared with nondiabetic mice. Finally, 6-
month-old a1KOAkitaKO mice had a significant decline
(B50%) in glomerular filtration compared with 4-month-
old mice of the same genotype. Thus, we propose that the
integrin a1KOAkitaKO on a Balb/c background have many
of the features of human DN. In addition, they fulfill many
features of a good mouse model of DN as described by
the AMDCC, which include a 10-fold increase in urinary
albumin excretion, mesangiolysis, mesangial expansion,
nodular glomerulosclerosis, hyalinosis, 50% increase in
GBM thickening, and 50% decline in GFR over the lifetime
of the animal.3
Our studies agree with the observation that the Akita
mouse is a promising model of spontaneous type 1 DN.11
This mouse carries a mutation in the insulin-2 gene and
heterozygote mice develop spontaneous type 1 diabetes.10
The Akita-het mouse presents sustained and robust hyper-
glycemia, enhanced levels of albuminuria, and mesangial
pathology. However, the extent of proteinuria and mesangial
pathology is relatively modest in the original line of C57BL/6
Akita-het mice.11 As the genetic background has a strong
influence on the characteristics of kidney injury associated
with DN,21 novel lines of inbred Akita-het mice were
generated, resulting in increased albuminuria in these mice.12
However, parameters such as GFR and pathologic glomerular
changes still did not meet the AMDCC criteria.3
In this study, we successfully generated Balb/c Akita mice
with either one or both insulin-2 genes mutated, namely, the
Balb/c Akita-het or AkitaKO mice. Whereas Balb/c mice
appear to be relatively resistant to diabetic kidney disease,11,22
Balb/c Akita-het mice develop a moderate increase of GFR,
2-fold increase in albuminuria, and glomerulosclerosis within
6 months of age. This result agrees with the finding obtained
with Akita-het on the C57BL/6 background.12 Balb/C
AkitaKO mice have more pronounced proteinuria (3-fold
increased over nondiabetic mice), mesangial expansion, and
glomerulosclerosis, and while their GFR is significantly
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increased in 4-month-old mice, a B22% decline is observed
at 6 months when the mice usually die. Although promising,
these mice do not completely meet the AMDCC criteria,
which require 50% decline in GFR over the lifetime and
greater than a 10-fold increase in albuminuria.
To generate a more robust mouse model of type 1 DN,
we crossed the AkitaKO mice onto the integrin a1–null
background. Integrin a1b1 is a major collagen IV receptor,
highly expressed by glomerular cells, that has a key role in
negatively regulating the degree of glomerulosclerosis.15,16,18
We have shown that integrin a1b1 is a negative regulator of
glomerular collagen synthesis, which functions by negatively
regulating epidermal growth factor receptor activation,
generation of profibrotic reactive oxygen species, and
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Figure 9 |No significant evidence of tubulointerstitial fibrosis in a1KOAkitaKO Balb/c mice. (a) Electron microscopy pictures of tubules
of 6-month-old WT, AkitaKO, and a1KOAkitaKO mice. Bar¼ 2 mm. The values (in nm) represent the mean±s.d. of tubular basement
membrane thickness of 30 measurements. (b) Paraffin kidney sections were co-stained with Dolichos biflorus agglutinin (DBA) and anti-
collagen I (upper panel) or anti-a-smooth muscle action (a-SMA, lower panel). Merged images are shown. V, vessel. (c) Paraffin kidney
sections were co-stained with anti-mouse E-cadherin antibodies or DAPI. Merged images at both low and high magnification are shown.
DAPI, 4,6-diamidino-2-phenylindole; KO, knockout; WT, wild type.
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consequent collagen levels.23,24 More recently, we showed that
integrin a1b1 also exerts its anti-fibrotic role by regulating
both the level and phosphorylation state of caveolin-1,24,25 a
scaffolding protein that alters epidermal growth factor
receptor activation. Thus, integrin a1b1 protects mice from
glomerular injury by controlling many cell signaling path-
ways that regulate reactive oxygen species generation and
collagen synthesis. Consistent with these findings, Balb/c
integrin a1KO mice develop severe albuminuria, glomerulo-
sclerosis, thickening of the GBM, and altered GFR following
injection with streptozotocin.16 Here we show that Balb/C
AkitaKO mice crossed with the integrin a1KO mice back-
ground show 16-fold increase in albuminuria, significant
mesangial matrix expansion, glomerulosclerosis, nodular
glomerulosclerosis, mesangiolysis, and 2-fold increase in
GBM thickening when compared with nondiabetic mice.
Moreover, these mice present hyper-filtration at 4 months of
age, followed by a B50% decline by 6 months. At 6 months
of age, GFR in the a1KOAkitaKO mice reached the levels of
nondiabetic a1KO mice. Whether these mice could develop
further decline in GFR is at this point in time difficult to
determine, as they do not survive longer than 6 months.
Interestingly, neither the AkitaKO nor the a1KOAkitaKO
mice developed significant tubulointerstitial disease, despite
the severe glomerular lesions and heavy proteinuria.
Although this is similar to many mouse models of DN, it
contrasts with the eNOS/ mice, the db/db mice crossed
onto the eNOS/ background, and the Akita diabetic mice
crossed onto the bradykinin receptor–null mice where both
glomerular and tubulointerstitial changes occur.7,9,14,26 The
reason for the lack of tubulointerstitial changes in our model
is not known, but because some models do indeed develop
tubulointerstitial disease, it is likely dependent on the model
or the genetic background of the mice. Nevertheless, these
findings do bring into question whether the level of
proteinuria corresponds to the severity of interstitial disease
in the setting of DN.
Our studies are a continuation of the quest to generate a
better mouse model of DN by investigating animals that have
undergone genetic manipulation. One of the best-described
examples of these mice is the eNOS/ mouse. When this
mouse on the C57BL/6 background is rendered diabetic by
the injection of streptozotocin, it develops more severe DN
than wild-type controls.9 Diabetic eNOS/ mice developed
a 10-fold increase in albuminuria with low-dose streptozo-
tocin and a 40-fold increase with high-dose streptozotocin,
and they also developed significant increases in mesangial
expansion, focal sclerosis, and tubulointerstitial disease.
Although a promising model of DN, diabetes in these mice
is induced by streptozotocin, a drug with high toxicity and
high instability. To obviate streptozotocin treatment, the
C57BL/6 eNOS/ mice were also crossed onto the C57BL/6
Akita mice. The C57BL/6 eNOS//Akita mice die before
5 months of age; however, outbred C57/B6 Sv129 eNOS-
het/Akita or eNOS//Akita mice develop DN characterized
by mesangial expansion, nodular glomerulosclerosis,
proteinuria, and altered GFR.27 The renal characteristics
observed in these outbred mice are very similar to the ones
seen in the integrin a1KOAkitaKO mice on the pure Balb/c
background.
Interestingly, the eNOS/ mice have been also used to
worsen DN in type 2 diabetes induced by crossing the
eNOS/ mice with C57BLKS-db/db mice.7 These mice
exhibit marked albuminuria, progressive increase in serum
creatinine, and decrease in GFR.7 They also show mesangial
expansion, GBM thickening, focal nodular glomerulosclero-
sis, and mesangiolysis, as well as arteriolar hyalinosis.7 These
results, together with the ones reported in this study, suggest
that crossing the integrin a1KO mouse onto the C57BLKS-
db/db mouse might also result in a robust mouse model of
type 2 diabetes.
In conclusion, our study suggests that integrin a1KOAki-
taKO mice, with their significant decline in GFR, together
with the higher than 10-fold increase in albuminuria and
higher than 50% increase in GBM thickening, offer a mouse
model that carries key features of human DN, making
this strain particularly attractive for testing therapeutic
interventions.
MATERIALS AND METHODS
Animals
C57BL/6 Akita mice were purchased from The Jackson Laboratory
(Bar Harbor, ME). Inbred BALB/c Akita mice were generated by
backcrossing the Akita mutation onto the BALB/c background for
10 generations. Transmission of the Akita mutation (C96Y) and
successful generation of the Balb/c AkitaKO mice was assessed by
polymerase chain reaction (PCR) analysis of tail genomic DNA
(Supplementary Figure S1A and S1B online). To generate the
integrin a1KOAkitaKO mice, BALB/c integrin a1KO mice16 were
crossed with BALB/c-AkitaKO mice, and F1 siblings (a1hetAkitahet)
crossed among themselves to obtain the genotype required.
Successful generation of the Balb/c integrin a1KOAkitaKO mice
was assessed by PCR analysis of tail genomic DNA (Supplementary
Figure S1A and S1B online). Mice were housed in AALAC-
accredited animal facility following the National Institutes of Health
guidelines. Because of the limited hyperglycemia observed in
diabetic female mice, only male mice were studied.
Genotyping
The protocol for the Akita genotyping was obtained from The
Jackson Laboratory. Briefly, following PCR amplification of genomic
DNA using the sense 50-TGCTGATGCCCTGGCCTGCT-30 and
antisense 50-TGGTCCCACATATGCACATG-30 primers, the PCR
products were digested with Fnu4HI enzyme (NEB, R0178s) at
371C overnight and run onto 2% agarose gels (Sigma, St Louis, MO)
for detection of the wild-type (140 bp) and/or the mutant (280 bp)
allele. The protocol for genotyping integrin a1-null mice was as
previously described.28 Briefly, following PCR amplification of
genomic DNA using the wild-type 50-GTTGTTCTATTTTTGTAGT
TAAC-30; knockout 50-GGGGAACTTCCTGACTAG-30; and com-
mon 50-AATCCTCCATTCGGGTTGGTG-30 primers, the PCR
products were run onto 2% agarose gels for detection of the
wild-type (103 bp) and/or the knockout (273 bp) allele. Supple-
mentary Figure S1A and S1B shows the genotypes of mice used in
this study.
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Weight and blood glucose measurements
Body weight was measured weekly and expressed in grams. Blood
glucose levels were measured monthly between 08:30 and 10:30
hours using a OneTouch glucometer (LifeScan, Milpitas, CA) and
expressed as mg/dl. Approximately 5 ml of blood was collected in
conscious mice via tail vein puncture.
Urinary albumin measurement
For the analysis of albuminuria, 24-h urine collection was
performed in 4- and 6-month-old nondiabetic and diabetic mice,
and the concentration of urine albumin and creatinine was
measured using the ELISA Albuwell M test kit (Exocel, Philadelphia,
PA). The ratio of albumin/creatinine was expressed as mg/mg.
Measurement of GFR
Fluorescein isothiocyanate-inulin clearance was measured in con-
scious mice as previously described.22,29 Briefly, fluorescein isothio-
cyanate-inulin (5% in phosphate-buffered saline) was injected retro-
orbitally in 4- and 6-month-old nondiabetic and diabetic mice. At 3,
7, 10, 15, 35, 55, and 75min after the fluorescein isothiocyanate-
inulin injection, blood samples were obtained from the lateral
saphenous vein.30 Fluorescence intensity was measured at 485
excitation/520 emission using a FLUOstar Omega plate reader
(BMG Labtech, Cary, NC). Plasma fluorescence was fitted to a
two-phase exponential decay using nonlinear regression (GraphPad
Prism), and GFR was calculated using standard formulas and is
reported as microliters per minute per gram body weight.
Renal histology
Kidneys were collected from 4- and 6-month-old nondiabetic and
diabetic mice for histological analysis. Kidneys were immediately
fixed in 4% formaldehyde and then embedded in paraffin. Sections
of paraffin-embedded kidneys were either subjected to periodic
acid–Schiff, Masson’s trichrome, or Jones’ staining. The mesangial
sclerosis index was evaluated in a blinded manner as previously
described.31 Briefly, the percentage of mesangial matrix occupying
each glomerulus was rated as 1, 0–24%; 2, 25–49%; 3, 50–74%; and 4,
475%. Kidneys from six mice per genotype with a total of 120
glomeruli were analyzed and the mesangial sclerosis index expressed
as mean±s.d.
Immunofluorescence and immunohistochemistry
Paraffin kidney sections were co-stained with Dolichos biflorus
agglutinin and rabbit anti-mouse collagen I antibodies (1:100;
Biodesign, Saco, ME) or rabbit-anti-mouse a-smooth muscle actin
(1:100; Sigma), followed by rhodamine-conjugated goat anti-rabbit
IgG (1:200; Jackson Immunoresearch, West Grove, PA). Paraffin
kidney sections were also stained with rabbit anti-mouse E-cadherin
(1:100; Sigma) or rabbit anti-mouse collagen IV antibodies (1:100;
Biodesign), followed by rhodamine-conjugated or horseradish
peroxidase–conjugated goat anti-rabbit IgG (1:200; Jackson
Immunoresearch). The levels of glomerular collagen IV deposition
were analyzed using the Bioquant Image analysis software (Bioquant
Image Analysis, Nashville, TN). Collagen IV was expressed as the
percentage of area occupied by collagen IV–positive structures per
glomerulus. Kidneys from six mice per genotype with a total of 120
glomeruli were evaluated.
Frozen kidney sections were stained with rat anti-mouse CD31
antibodies (1:500, Santa Cruz Biotechnology, Santa Cruz, CA),
followed by rhodamine-conjugated goat anti-rat IgG (1:200; Jackson
Immunoresearch). The degree of vascularization, expressed as the
percentage of area occupied by CD31-positive structures/glomerulus,
was evaluated using the Scion Imaging Software (Frederick, MD),32
using five glomeruli/mouse and four mice/genotype.
Electron microscopy
Portions of renal cortex from 4- and 6-month-old nondiabetic and
diabetic mice were fixed in 2.5% glutaraldehyde in phosphate buffer.
Samples were postfixed in OsO4, dehydrated in ethanol, and
embedded in resin. Glomeruli and tubules were then selected from
toluidineblue-stained thick sections and cut for thin sections.
Ultrastructural assessment of glomerular and tubular pathologic
changes was performed using a Morgagni transmission electron
microscope (FEI, Eindhoven, The Netherlands). Glomerular and
tubular basement membrane thickening was assessed by point-to-
point measurements using a 2X2K camera (Advanced Microscopy-
Techniques, Danvers, MA) with the associated digital imaging
software. Ten different segments of glomerular or tubular basement
membrane per mouse from three mice were measured with a total of
30 measurements in each group.
Statistical analysis
The values for each parameter within a group are expressed as
mean±s.d. For comparisons between two experimental groups, an
unpaired t-test was used to assess statistical significance. For
comparisons among multiple groups, analysis of variance with
Tukey’s multiple comparisons test was used. Po0.05 was considered
statistically significant.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
These studies were in part supported by a Merit Review from the
Department of Veterans Affairs (AP, RZ, RCH) and the NIH grants:
2P01DK065123 (AP and RZ); DK075594, and DK083187 (RZ);
DK051265 and DK062794 (RCH); DK061018 (AMDCC) (RCH, AP);
AHA established investigator award (RZ); the O’Brien P30DK79341-01
(AP, RZ, RCH).
SUPPLEMENTARY MATERIAL
Figure S1. Generation of AkitaKO and integrin a1KOAkitaKO Balb/c
mice.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
REFERENCES
1. Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic
kidney disease: the role of metabolic, hemodynamic, intracellular factors
and growth factors/cytokines. Endocr Rev 2004; 25: 971–1010.
2. van Dijk C, Berl T. Pathogenesis of diabetic nephropathy. Rev Endocr
Metab Disord 2004; 5: 237–248.
3. Brosius 3rd FC, Alpers CE, Bottinger EP et al. Mouse models of diabetic
nephropathy. J Am Soc Nephrol 2009; 20: 2503–2512.
4. Breyer MD, Bottinger E, Brosius 3rd FC et al. Mouse models of diabetic
nephropathy. J Am Soc Nephrol 2005; 16: 27–45.
5. Tesch GH, Lim AK. Recent insights into diabetic renal injury from the
db/db mouse model of type 2 diabetic nephropathy. Am J Physiol Renal
Physiol 2011; 300: F301–F310.
6. Sharma K, McCue P, Dunn SR. Diabetic kidney disease in the db/db
mouse. Am J Physiol Renal Physiol 2003; 284: F1138–F1144.
7. Zhao HJ, Wang S, Cheng H et al. Endothelial nitric oxide synthase
deficiency produces accelerated nephropathy in diabetic mice. J Am Soc
Nephrol 2006; 17: 2664–2669.
8. Hudkins KL, Pichaiwong W, Wietecha T et al. BTBR Ob/Ob mutant mice
model progressive diabetic nephropathy. J Am Soc Nephrol 2010; 21:
1533–1542.
1096 Kidney International (2012) 81, 1086–1097
or ig ina l a r t i c l e L Yu et al.: Integrin a1b1 and diabetic nephropathy
9. Kanetsuna Y, Takahashi K, Nagata M et al. Deficiency of endothelial nitric-
oxide synthase confers susceptibility to diabetic nephropathy in
nephropathy-resistant inbred mice. Am J Pathol 2007; 170: 1473–1484.
10. Yoshioka M, Kayo T, Ikeda T et al. A novel locus, Mody4, distal to
D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese
C57BL/6 (Akita) mutant mice. Diabetes 1997; 46: 887–894.
11. Gurley SB, Clare SE, Snow KP et al. Impact of genetic background on
nephropathy in diabetic mice. Am J Physiol Renal Physiol 2006; 290:
F214–F222.
12. Gurley SB, Mach CL, Stegbauer J et al. Influence of genetic background on
albuminuria and kidney injury in Ins2(+/C96Y) (Akita) mice. Am J Physiol
Renal Physiol 2010; 298: F788–F795.
13. Wong DW, Oudit GY, Reich H et al. Loss of angiotensin-converting enzyme-
2 (Ace2) accelerates diabetic kidney injury. Am J Pathol 2007; 171: 438–451.
14. Kakoki M, Sullivan KA, Backus C et al. Lack of both bradykinin B1 and B2
receptors enhances nephropathy, neuropathy, and bone mineral loss in
Akita diabetic mice. Proc Natl Acad Sci USA 2010; 107: 10190–10195.
15. Chen X, Moeckel G, Morrow JD et al. Lack of integrin alpha1beta1 leads to
severe glomerulosclerosis after glomerular injury. Am J Pathol 2004; 165:
617–630.
16. Zent R, Yan X, Su Y et al. Glomerular injury is exacerbated in diabetic
integrin alpha1-null mice. Kidney Int 2006; 70: 460–470.
17. Jerums G, Premaratne E, Panagiotopoulos S et al. The clinical significance
of hyperfiltration in diabetes. Diabetologia 2010; 53: 2093–2104.
18. Gardner H, Broberg A, Pozzi A et al. Absence of integrin alpha1beta1 in
the mouse causes loss of feedback regulation of collagen synthesis in
normal and wounded dermis. J Cell Sci 1999; 112(Part 3): 263–272.
19. Futrakul N, Futrakul P. Vascular homeostasis and angiogenesis determine
therapeutic effectiveness in type 2 diabetes. Int J Vasc Med 2011; 2011:
971524.
20. Holthofer H, Schulte BA, Spicer SS. Expression of binding sites for
Dolichos biflorus agglutinin at the apical aspect of collecting duct cells in
rat kidney. Cell Tissue Res 1987; 249: 481–485.
21. Breyer MD, Qi Z, Tchekneva EE et al. Insight into the genetics of diabetic
nephropathy through the study of mice. Curr Opin Nephrol Hypertens
2008; 17: 82–86.
22. Qi Z, Fujita H, Jin J et al. Characterization of susceptibility of inbred mouse
strains to diabetic nephropathy. Diabetes 2005; 54: 2628–2637.
23. Chen X, Abair TD, Ibanez MR et al. Integrin alpha1beta1 controls reactive
oxygen species synthesis by negatively regulating epidermal growth
factor receptor-mediated Rac activation. Mol Cell Biol 2007; 27:
3313–3326.
24. Chen X, Whiting C, Borza C et al. Integrin alpha1beta1 regulates
epidermal growth factor receptor activation by controlling peroxisome
proliferator-activated receptor gamma-dependent caveolin-1 expression.
Mol Cell Biol 2010; 30: 3048–3058.
25. Borza CM, Chen X, Mathew S et al. Integrin {alpha}1{beta}1 promotes
caveolin-1 dephosphorylation by activating T cell protein-tyrosine
phosphatase. J Biol Chem 2010; 285: 40114–40124.
26. Nakagawa T, Sato W, Glushakova O et al. Diabetic endothelial nitric oxide
synthase knockout mice develop advanced diabetic nephropathy.
J Am Soc Nephrol 2007; 18: 539–550.
27. Wang CH, Li F, Hiller S et al. A modest decrease in endothelial NOS in
mice comparable to that associated with human NOS3 variants
exacerbates diabetic nephropathy. Proc Natl Acad Sci USA 2011; 108:
2070–2075.
28. Gardner H, Kreidberg J, Koteliansky V et al. Deletion of integrin alpha 1 by
homologous recombination permits normal murine development but
gives rise to a specific deficit in cell adhesion. Dev Biol 1996; 175:
301–313.
29. Qi Z, Whitt I, Mehta A et al. Serial determination of glomerular filtration
rate in conscious mice using FITC-inulin clearance. Am J Physiol Renal
Physiol 2004; 286: F590–F596.
30. Hem A, Smith AJ, Solberg P. Saphenous vein puncture for blood sampling
of the mouse, rat, hamster, gerbil, guinea pig, ferret and mink. Lab Anim
1998; 32: 364–368.
31. Yu L, Border WA, Anderson I et al. Combining TGF-beta inhibition and
angiotensin II blockade results in enhanced antifibrotic effect. Kidney Int
2004; 66: 1774–1784.
32. Pozzi A, Moberg PE, Miles LA et al. Elevated matrix metalloprotease
and angiostatin levels in integrin alpha 1 knockout mice cause reduced
tumor vascularization. Proc Natl Acad Sci USA 2000; 97: 2202–2207.
Kidney International (2012) 81, 1086–1097 1097
L Yu et al.: Integrin a1b1 and diabetic nephropathy o r ig ina l a r t i c l e
